Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Zeo ScientifiX's Sloan Ratio for the quarter that ended in Jan. 2024 was 0.00%.
Warning Sign:
When sloan ratio (-194.32)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Jan. 2024, Zeo ScientifiX has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Zeo ScientifiX Sloan Ratio % Historical Data
The historical data trend for Zeo ScientifiX's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zeo ScientifiX's Sloan Ratio %
For the Biotechnology subindustry, Zeo ScientifiX's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeo ScientifiX's Sloan Ratio % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's Sloan Ratio % falls into.
Zeo ScientifiX Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Zeo ScientifiX's Sloan Ratio for the fiscal year that ended in Oct. 2023 is calculated as
Zeo ScientifiX's Net Income for the trailing twelve months (TTM) ended in Jan. 2024 was -1.991 (Apr. 2023 ) + -1.618 (Jul. 2023 ) + -1.091 (Oct. 2023 ) + -1040 (Jan. 2024 ) = $-1,045 Mil.
Zeo ScientifiX's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jan. 2024 was 1281.046 (Apr. 2023 ) + -0.464 (Jul. 2023 ) + 0.22 (Oct. 2023 ) + -575 (Jan. 2024 ) = $706 Mil.
Zeo ScientifiX's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jan. 2024 was 15.884 (Apr. 2023 ) + -0.004 (Jul. 2023 ) + 0.735 (Oct. 2023 ) + 0 (Jan. 2024 ) = $17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeo ScientifiX (OTCPK:ZEOX) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jan. 2024, Zeo ScientifiX has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Zeo ScientifiX Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Zeo ScientifiX's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Zeo ScientifiX (Zeo ScientifiX) Business Description
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZEOX has been successfully added to your 